Abstract

Introduction/BackgroundCombination of immunotherapy with carboplatin/paclitaxel (CP) has demonstrated improved progression-free survival (PFS) and overall survival (OS) in patients with advanced endometrial cancer. The Phase III DUO-E/GOG-3041/ENGOT-EN10 trial (NCT04269200) evaluated the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Tumor board presentation of a woman with metastatic, hormone receptor‐positive, mismatch repair‐deficient endometrial cancer
Kathryn A Mills ... Gini F Fleming
CA: A Cancer Journal for Clinicians | VOL. 72
Kathryn A Mills, et. al.Kathryn A Mills ... Gini F Fleming
25 Jan 2022
633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Angeles Alvarez Secord ... Mansoor Raza Mirza
International Journal of Gynecologic Cancer | VOL. 34
Angeles Alvarez Secord, et. al.Angeles Alvarez Secord ... Mansoor Raza Mirza
01 Mar 2024
625 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: analysis of progression-free survival and overall survival outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Joseph Buscema ... Kellie Schneider
International Journal of Gynecologic Cancer | VOL. 34
Joseph Buscema, et. al.Joseph Buscema ... Kellie Schneider
01 Mar 2024
589 RUBY trial post hoc analysis of number needed to treat and incremental costs per outcome of dostarlimab + carboplatin-paclitaxel (CP) vs placebo + CP for primary advanced/recurrent endometrial cancer
Lydia Lee ... Meghann Gregg
Journal for ImmunoTherapy of Cancer | VOL. 11
Lydia Lee, et. al.Lydia Lee ... Meghann Gregg
01 Nov 2023
View more papers

More From: International Journal of Gynecologic Cancer

Paper Title
Journal
Date
Author
Can international standards in ovarian cancer treatment be attained by low- and middle-income countries?
Daniel Sanabria ... Adriana Ramos
International Journal of Gynecologic Cancer | VOL. -
Daniel Sanabria, et. al.Daniel Sanabria ... Adriana Ramos
24 May 2024
Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer
Eric Rios-Doria ... Mario M Leitao
International Journal of Gynecologic Cancer | VOL. -
Eric Rios-Doria, et. al.Eric Rios-Doria ... Mario M Leitao
23 May 2024
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)
Agnieszka Michael ... Jonathan Ledermann
International Journal of Gynecologic Cancer | VOL. -
Agnieszka Michael, et. al.Agnieszka Michael ... Jonathan Ledermann
17 May 2024
Predictive value of SUVmax from initial 18F-FDG PET/CT scans for treatment outcomes in endometrial cancer patients undergoing fertility sparing management
Ok-Ju Kang ... Jeong-Yeol Park
International Journal of Gynecologic Cancer | VOL. -
Ok-Ju Kang, et. al.Ok-Ju Kang ... Jeong-Yeol Park
16 May 2024
View more papers